老龄急性髓系白血病异基因造血干细胞移植的预处理进展

Advances in conditioning regimens for allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia

异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)是目前唯一可能治愈急性髓系白血病(acute myeloid leukemia,AML)的方法。AML的发病中位年龄为68岁,加之人口老龄化的必然趋势,老龄AML患者(60岁及以上)的allo-HSCT领域成为当今研究热点。预处理方案的选择往往对allo-HSCT受者的临床结局起决定性作用。本综述分别总结了经典及最新的预处理方案,并对其产生的临床结局进行比较,以明确不同预处理方案的优势,从而对老龄AML患者进行量身定制地选择。

Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is a sole viable treatment for acute myeloid leukemia(AML).As the median age of AML is approaching 68 years and the global population is aging,allo-HSCT for is becoming more vital for elderly AML patients(60 years and over).Conditioning regimen is important in determining the clinical outcomes of post-allo-HSCT patients.This review summarized the classic and latest conditioning regimens and evaluated their respective clinical outcomes.Clinicians may appreciate the advantages of each conditioning regimen and formulate optimal options for elderly AML patients.